We found that treatment of PCNA-I1S in combination with DNA damaging agents Cs-137, UV-C, or cisplatin (cisPt) produced additive inhibitory effects on growth of prostate cancer and NSCLC cells. The gene discussed is PCNA; the disease is prostate carcinoma.